Head and Neck Cancer Clinical Trial
Official title:
Phase I Study of Bortezomib and Cetuximab Without or With Cisplatin in Combination With Radiation Therapy for Advanced Head and Neck Cancer
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Monoclonal antibodies, such as cetuximab, can block tumor growth in
different ways. Some block the ability of tumor cells to grow and spread. Others find tumor
cells and help kill them or carry tumor-killing substances to them. Radiation therapy uses
high energy x- rays to kill tumor cells. Bortezomib and cetuximab may make tumor cells more
sensitive to radiation therapy. Drugs used in chemotherapy, such as cisplatin, work in
different ways to stop the growth of tumor cells, either by killing the cells or by stopping
them from dividing. Giving bortezomib together with cetuximab, radiation therapy, and
cisplatin may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of bortezomib when
given together with cetuximab and radiation therapy with or without cisplatin in treating
patients with stage IV head and neck cancer.
Status | Completed |
Enrollment | 46 |
Est. completion date | |
Est. primary completion date | December 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
DISEASE CHARACTERISTICS: - Histologically or cytologically confirmed squamous cell carcinoma of the head and neck, including variants or undifferentiated/poorly differentiated carcinoma - Previously untreated stage IV disease OR residual disease or regionally recurrent disease after prior surgery and/or chemotherapy - Must be eligible to receive full-dose radiotherapy and be evaluated and accepted for treatment by a Radiation Oncologist - No clinically measurable distant disease OR has asymptomatic small distant lesions outside the radiation field = 3 cm in individual or aggregate diameter for which palliation of local and regional disease is clearly warranted - No previously untreated nasopharyngeal cancer (any stage) - Recurrent nasopharyngeal carcinoma allowed - No known brain metastases PATIENT CHARACTERISTICS: - ECOG performance status (PS) 0-1 OR Karnofsky PS 70-100% - ANC = 1,500/mcL - Platelet count = 100,000/mcL - Total bilirubin normal (indirect bilirubin = 3 mg/dL in patients with Gilbert's syndrome) - AST and ALT = 2.5 times upper limit of normal - Creatinine normal OR creatinine clearance = 60 mL/min - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - Adequate cognitive and neurologic function - No history of allergic reactions attributed to compounds of similar chemical or biologic composition to bortezomib, cetuximab, cisplatin, or other agents used in this study - No peripheral sensory neuropathy = grade 2 - No concurrent uncontrolled illness including, but not limited to, the following: - Ongoing or active infection - Symptomatic congestive heart failure - Unstable angina pectoris - Cardiac arrhythmia - Psychiatric illness/social situations that would preclude study compliance - HIV-negative PRIOR CONCURRENT THERAPY: - See Disease Characteristics - Recovered from prior therapy - At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C) - More than 3 months since prior cisplatin - No prior radiotherapy to the head and neck - No prior systemic EGFR inhibitors - No prior bortezomib - No other concurrent investigational agents - No other concurrent anticancer therapy - No concurrent antiretroviral therapy - No concurrent prophylactic filgrastim (G-CSF) or sargramostim (GM-CSF) - No concurrent amifostine |
Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office | Bethesda | Maryland |
United States | UPMC Cancer Centers | Pittsburgh | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Dose-limiting toxicities and other toxicities as assessed by NCI CTCAE v3.0 | Yes | ||
Primary | Maximum tolerated dose of bortezomib when administered in combination with cetuximab and radiotherapy with and without cisplatin | Yes | ||
Secondary | Objective response rate | No | ||
Secondary | Progression-free survival | No | ||
Secondary | Overall survival | No | ||
Secondary | Pre-to-post-treatment changes in biomarkers | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05808920 -
The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03997643 -
Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04700475 -
Effect of Low Level Laser Therapy on Prevention of Radiotherapy Induced Xerostomia in Cancer Patients.
|
N/A | |
Withdrawn |
NCT04058145 -
AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT02572869 -
Functional and Aesthetic Outcomes After Mandible Reconstruction With Fibula Osteomyocutaneous Free Flaps
|
||
Active, not recruiting |
NCT04474470 -
A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05073809 -
Photoacoustic Imaging of Head and Neck Tumours
|
||
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT03651570 -
Randomized Controlled Trial of a E-intervention to Help Patients Newly Diagnosed With Cancer Cope Better: Pilot Study
|
N/A | |
Recruiting |
NCT04930432 -
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06016699 -
Immunological Function After Radiation With Either Proton or Photon Therapy
|
||
Terminated |
NCT03843554 -
Commensal Oral Microbiota in Head and Neck Cancer
|
N/A | |
Recruiting |
NCT05915572 -
Mulligan Technique on Shoulder Dysfunction
|
N/A | |
Completed |
NCT05897983 -
Tens and Rocabado Exercises on TMJ Dysfunction
|
N/A | |
Not yet recruiting |
NCT06289049 -
Heavy Strength Training in Head and Neck Cancer Survivors
|
Phase 2 | |
Withdrawn |
NCT05263648 -
Virtual Reality Software to Reduce Stress in Cancer Patients
|
N/A | |
Withdrawn |
NCT03238638 -
A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy
|
Phase 2 |